Close
CDMO Safety Testing 2026
Novotech

Baxter in Manesar,Waluj and Alathur

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.
- Advertisement -

Baxter in Manesar:

Baxter’s facility in Manesar, Gurgaon demonstrates excellence in manufacturing for the company’s Medication Delivery and Renal businesses, producing IV and PD solutions.

The 21,000 sq.m. facility in Manesar was constructed by Baxter in 2002. The campus is designed for critical processing of sterile parenteral products and includes a Chemistry Lab, Microbiology Lab, Calibration Lab along with a central warehouse and administrative offices. The site also includes critical batch mixing/compounding operations, and has specialized packaging capabilities. In 2003 and 2005 it won the Ecoprofit Certification for ‘Cleaner Production and Environment Management’ and was one of the first to be granted a license to manufacture under the revised Schedule M of the Drugs and Cosmetics Act. The plant has recently expanded in capacity and is also vertically integrated to manufacture plastic parts. It is ISO13485 certified, enabling it to manufacture CE grade devices and employs 450 personnel.

Baxter in Waluj :

Baxter’s facility in Waluj, Maharashtra manufactures Large Volume Parenterals. It uses state of the art Form-Fill-Seal technology. It is a Large Volume Infusion plant on the outskirts of Aurangabad, Maharashtra.

It has Modern Quality Control Laboratories & Support systems to ensure compliance with GMP Guidelines. The plant operates in a continuous cycle of Formulation, Filling, Terminal sterilization and Packing activities. The over 52,000 sq. m. facility employs around 128 employees and caters to both the domestic and export markets.

Baxter in Alathur :

Baxter’s facility in Alathur is located about 50 kilometers south of Chennai, Tamil Nadu. The plant manufactures Large Volume Parenterals using state of the art Form-Fill-Seal technology.

The plant has Modern Quality Control Laboratories & Support systems to ensure compliance with GMP Guidelines .The plant operates in a continuous cycle of Formulation, Filling, Terminal sterilization and Packing activities. The over 39,000 sq. m. facility employs around 114 employees and caters to both the domestic and export markets.

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.

AbbVie to Invest $1.4B in North Carolina Manufacturing Plant

AbbVie has outlined plans to build a major new...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »